Cargando…

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events

Prostate cancer has a very high prevalence among elder men, and this could potentially increase as longevity in many parts of the world is increasing. Early stages of prostate cancer can have surgical options, but the more advanced stages require some form of anti-androgen therapy. There are novel a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Aswini, Reddy, Aswanth, Sekar, Arjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887759/ https://www.ncbi.nlm.nih.gov/pubmed/36721244 http://dx.doi.org/10.1186/s40959-023-00160-7

Ejemplares similares

A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

Correction: A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan
por: Reddy, Aswanth, et al.
Publicado: (2023)

An unusual cause of chronic diarrhea in a Middle‐Aged adult: A diagnostic challenge
por: Reddy, Aswanth, et al.
Publicado: (2023)

A case report of abscopal toxicity in a patient with lung adenocarcinoma
por: Reddy, Aswanth, et al.
Publicado: (2023)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Unusual presentation of pulmonary nocardiosis as pyopneumothorax in HIV
por: Kumar, Aswini, et al.
Publicado: (2015)

Decompensated Non-Ischemic Cardiomyopathy Induced by Anabolic-Androgenic Steroid Abuse
por: Sodhi, Palwinder, et al.
Publicado: (2020)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Objective criteria for septal fibrosis in non-ischemic dilated cardiomyopathy: validation for the prediction of future cardiovascular events
por: Mikami, Yoko, et al.
Publicado: (2016)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Androgen Receptor Blockade Using Enzalutamide Suppresses Long Non-Coding RNA ARLNC1 in Prostate Cancer Cells
por: Huseynova, Günel, et al.
Publicado: (2022)

Cardiac resynchronization therapy in ischemic and non-ischemic cardiomyopathy
por: Yokoshiki, Hisashi, et al.
Publicado: (2017)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Can 3D RVEF be Prognostic for the Non-Ischemic Cardiomyopathy Patient but Not the Ischemic Cardiomyopathy Patient? A Cardiovascular MRI Study
por: Gill, Sartaj S., et al.
Publicado: (2019)

Quantitative characterization of myocardial infarction by cardiovascular magnetic resonance predicts future cardiovascular events in patients with ischemic cardiomyopathy
por: Yokota, Hajime, et al.
Publicado: (2008)

Cardiovascular dynamics in ischemic cardiomyopathy during exercise
por: van der Wall, E. E., et al.
Publicado: (2009)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following abiraterone or enzalutamide resistance: A systematic review
por: You, Xiangyun, et al.
Publicado: (2023)

Cardiovascular toxicities associated with abiraterone compared to enzalutamide–A pharmacovigilance study
por: Cone, Eugene B., et al.
Publicado: (2021)

Ventricular Tachycardia Ablation in Non-ischemic Cardiomyopathy
por: Bhaskaran, Ashwin, et al.
Publicado: (2019)

Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
por: Ito, Yusuke, et al.
Publicado: (2018)

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance
por: Nicolescu, Radu Costin Bizga, et al.
Publicado: (2022)

Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells
por: Pillai, Prathesha, et al.
Publicado: (2021)

Different expression and prognostic value of troponin in ischemic cardiomyopathy and non-ischemic dilated cardiomyopathy
por: Gao, Wei, et al.
Publicado: (2023)

Social Inequalities in Non-ischemic Cardiomyopathies
por: Amiya, Eisuke
Publicado: (2022)

Accurate Classification of Non-ischemic Cardiomyopathy
por: Wang, Yifan, et al.
Publicado: (2023)

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression()
por: Li, Zhenghong, et al.
Publicado: (2020)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
por: Lin, T-H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_33dn7rrhp0dcfh49m18sojiq5r